A randomized phase II clinical trial has been designed and started in the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) to select the better regimen between tailored CPT-11 + S-1 and the standard S-1 treatment for advanced or recurrent gastric cancer as the first line chemotherapy. Selection of the better treatment for general clinical practice in this clinical trial will lead to a more precise assignment of a promising regimen for a future phase III randomized trial, placing continuous 5-FU infusion as the reference arm. In this trial, subsidiary pharmacokinetic analysis for the tailored dose arm is also proposed. In order to continue chemotherapy for a long time and to obtain longer survival, our study design for the tailored therapy could be exploited, especially in the field of general clinical practice.
INTRODUCTION
A standard chemotherapy for advanced gastric cancer has not yet been established worldwide. In Japan, to date, no chemotherapeutic agent or combination of agents better than continuous infusion of 5-FU (5FUci) have been reported in any relevant clinical trials (1) . Therefore, the 5FUci regimen is still regarded as the most acceptable reference arm in Japanese randomized clinical trials for advanced gastric cancer. In 1999, however, a new anticancer drug S-1 was developed (2) , which has been expected to be a potentially promising agent for gastric cancer. Response rates of S-1 in two Japanese late phase II clinical trials for advanced gastric cancer were 53.6% (3) and 44.6% (4, 5) . It has been reported that S-1 induced complete remission even in 5-FU resistant cases (6) . Moreover, phase II clinical trials of combination chemotherapy with S-1 and other drugs are on-going. Among these trials, phase I/II clinical trials of CPT-11 + S-1 have shown a response rate of greater than 50% with tolerable toxicity (7, 8) . Reduction of thymidylate synthase (TS) gene expression by CPT-11 has been reported (9) , and a positive correlation between topoisomerase-I and TS has been suggested as a mechanism of the synergistic effect of the combination of these two chemotherapeutic agents (10, 11) .
In certain patients, however, severe toxicities even at a much lower dose than the maximum tolerated dose (MTD) have been observed in general clinical practices of the CPT-11/S-1 combination therapies. In order to reduce the considerably high toxicity of this regimen, we have proposed a tailored dose chemotherapy (12, 13) in order to improve compliance, prolong the drug administration period and eventually prolong survival.
Comparison of this tailored dose CPT-11/S-1 combination with the standard S-1 administration in this randomized phase II trial will be utilized for the selection of one of the best candidate treatment arms for a future large scale randomized phase III study that will be performed by placing 5FUci as the reference arm.
PROTOCOL DIGEST OF THE STUDY

PURPOSE
To select the better treatment between tailored CPT-11/S-1 arm and the standard S-1 chemotherapy arm as the first line treatment for advanced/recurrent gastric cancer patients, and to investigate which one of the two regimens is a better candidate for a future phase III randomized trial, as compared to 5FUci treatment.
The trial is an open-label, randomized controlled phase II clinical trial. The protocol was approved by the Protocol Review Committee of the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC).
RESOURCES
Research grants from the JFMC. 
REGISTRATION
Eligibility criteria checking report form will be sent to the JFMC Data Center after confirmation of the above criteria. Patients will then be allocated using dynamic randomization and registered either into Arm A or B. Information regarding the necessary follow-up examinations and recommended chemotherapy schedule will then be sent from the Data Center.
TREATMENT METHODS
Arm A: CPT-11 (75 mg/m 2 ) was administered biweekly as one-hour intravenous infusion for 4 weeks (one cycle). If the manifested toxicity (excluding diarrhea) defined by NCI-CTC criteria was found to be 0 or 1 during the first cycle, the dose of CPT-11 will be increased by 25 mg/m 2 raising the total dose to 100 mg/m 2 . If grade 2 toxicity is observed, the same dose will be maintained, and if toxicities of grade 3 and more are observed, the dose of CPT-11 will be decreased by 25 mg/m 2 , reducing the dose to 50 mg/m 2 for the second cycle. The dose adjustment will be repeated in every cycle in the same manner. A starting dose of 75 mg/m 2 of CPT-11 was determined on the basis of the MTD (125 mg/m 2 ) and the recommended dose (100 mg/m 2 ) defined by the previous phase I/II studies on the combination CPT-11 and S-1 therapy (7).
S-1 was administered in one of the following doses twice daily, after breakfast and dinner; body surface area (BSA) <1.25 m 2 , 40 mg; 1.25 m 2 < BSA < 1.50 m 2 , 50 mg; BSA ≥1.5 m 2 , 60 mg. S-1 was administered at the respective dose for 14 days, followed by a 14-day rest period (one cycle). Dose reduction will be performed with the same criteria as the original S-1 administration schedule as followed in Arm B. The dose adjustment will be repeated in every cycle in the same manner.
Arm B: Single-agent S-1 was administered in the same dose as that in Arm A, and for 28 days, followed by a 14-day rest period (one cycle), which is the original schedule defined by a phase I study on S-1.
FOLLOW-UP
Patients should be examined by their physicians every week before the administration of CPT-11 or/and S-1. Measurements of the size of the lesions are performed by imaging techniques such as CT every 4 weeks. The physician should record the data including toxicity and report to the Data Center every 4 weeks.
STUDY DESIGN AND STATISTICAL METHODS
The sample size was estimated to be 37 to select the better treatment with probability P = 0.90 based on the expectation that a 15% difference will be observed in the response rates between the two arms (14) . Taking ineligible patients into account, the sample size was set at 45 for each arm.
SUBSIDIARY ANALYSIS FOR THE TAILORED THERAPY
A relevant clinical trial of tailored dose chemotherapy has not been reported, except in an adjuvant chemotherapy trial for breast cancer (12) . In order to examine the exploitability of the tailored dose chemotherapy for gastric cancer, we have designed this randomized phase II trial, placing the tailored therapy arm in the prospective study.
We have previously developed and proposed a new dosefinding system, 'the individualized maximum repeatable dose (iMRD)' (13), and achieved longer survival with less toxicity in 18 pancreatic cancer patients. It is of special interest whether our weekly dose adjustments using a maximum dose-limiting toxicity of grade 2 or 3 have any correlation with the enzymatic and pharmacokinetic characteristics of the individual patients in the present prospective trial.
To examine the effect of the tailored dose therapy, a subsidiary pharmacokinetic (PK) study was suggested in patients after a strict informed consent was obtained. We proposed to evaluate several factors such as Cmax, Tmax, AUC 0-24 of SN-38 and SN-38g as PK of CPT-11, and AUC 0-24 , AUC 0-∞ , t ½ of FT, 5-FU, Oxo, CDHP as PK of S-1 at the first cycle and the third cycle.
By analyzing the above data, we expect to elucidate the correlation between the PK of these drugs at the first cycle and adjustment dose (dose at third cycle), and compare the PK of these drugs at the third cycle in every adjustment dose, which is thought to be the individual optimal dose. 
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